62 Docetaxel forlængede median- tiden til progression (24, 6 uger vs 15, 6 uger; p < 0, 01) og median - overlevelse (15, 3 måneder vs 12, 7 måneder; p = 0, 03) uden at påvirke det primære endepunkt (32% vs 25%, p = 0, 10), samlet respons rate (32% vs 25%, p = 0, 10).
Without affecting the primary endpoint, overall response rate (32% vs 25%, p = 0.10), docetaxel prolonged median time to progression (24.6 weeks vs 15.6 weeks; p < 0.01) and median survival (15.3 months vs 12.7 months; p = 0.03).